Journal of Chromatography B · 2019 · 63 citations · 11 references
PharmacyPharmaceutical AnalysisPharmacologyChromatographic AnalysisClinical PharmacologyMass Spectrometric AnalysisAnalytical ChromatographyBioanalytical Method ValidationChromatographic Method ValidationChromatographyLiquid ChromatographyMass SpectrometryBioanalytical ChromatographyChromatographic ValidationInternal StandardsLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisPlasma SamplingPlasma Stability AssaysUltra-performance Liquid Chromatography-mass Spectrometry
The development and full validation of a sensitive and selective ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) method are described for the simultaneous analysis of afatinib, alectinib, crizotinib and osimertinib in human lithium heparinized plasma. Afatinib-d6, crizotinib-d5 and erlotinib-d6 were used as internal standards. Given osimertinib's instability in plasma and whole blood at ambient temperature, samples should be solely processed on ice (T = 0 °C). Chromatographic separation was obtained on an Acquity UPLC ® BEH C18; 2.1 × 50 mm, 1.7 μm column, which was eluted with 0.400 mL/minute flow on a linear gradient, consisting of 10 mM ammonium formate (pH 4.5) and acetonitrile. Calibration curves for all compounds were linear for concentration ranges of 1.00 to 100 ng/mL for afatinib and 10.0 to 1000 ng/mL for alectinib, crizotinib and osimertinib, herewith validating the lower limits of quantification at 1.00 ng/mL for afatinib and 10.0 ng/mL for alectinib, crizotinib and osimertinib. Within-run and between-run precision measurements fell within 10.2%, with accuracy ranging from 89.2 to 110%.
11
Maria E. Arcila, Geoffrey R. Oxnard, Khédoudja Nafa et al. · Clinical Cancer Research · 2011 · 574 citations · Full text
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
JG Kuiper, Daniëlle A.M. Heideman, Erik Thunnissen et al. · Lung Cancer · 2014 · 208 citations